Companion Diagnostics Development Services Market: Distribution by Type of Service Offered, Analytical Technique Used, Therapeutic Areas and Key Geographies: Industry Trends and Global Forecasts, 2022-2035

Over the past few years, the improved understanding of molecular mechanisms involved in disease pathogenesis has resulted in the development of several targeted therapies. These therapies are tailored to target specific disease-related molecular signatures and require appropriate companion diagnostics (CDx) in order to make physicians aware of patients’ unique genetic profiles, enabling them to make informed treatment related decisions. These tests are most often developed parallel to an investigational drug in order to identify the latter’s safety and efficacy and measure its therapeutic effect on the target. With the approval of trastuzumab and HercepTest™ (an IHC-based companion diagnostic assay designed for determination of HER2 overexpression) by the USFDA in 1998, several novel targeted cancer drugs guided by a diagnostic assay, have progressed into clinical stages or are approved for commercial use. In fact, since 2020, a total of 44 companion diagnostics have been approved by the USFDA. Further, a study of nearly 200 unique pharmacological interventions evaluated across more than 670 clinical trials, suggests that the likelihood of a lead compound passing through various phases of clinical development and eventually getting approved is only 11%. The use of disease-specific biomarker information to recruit patients not only increases the success rates of the studies, but also reduces the trial costs by nearly 60%.

Given the various benefits, the healthcare industry is gradually shifting from the conventional, one-drug-for-all, paradigm to using tailored pharmacological interventions, which is expected to increase the need for companion diagnostics as well. However, given the complexities involved in the co-development of a drug and the affiliated companion diagnostic test, drug developers have demonstrated the preference to outsource the diagnostics development operations. In fact, around 80% of the companies are known to rely on third-party service providers for companion diagnostics development, primarily owing to the lack of in-house expertise for the development of these tests. As a result, many companies have made heavy investments in order to install robust tools and technologies, such as polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), next generation sequencing (NGS) and offer end-to-end services to sponsor companies engaged in this domain. In addition to conventional analytical techniques, several innovators have made latest upgrades in their portfolio by installing novel solutions, including digital PCR (dPCR) and digital immunoassay, in order to cater to the evolving needs of their customers. Given the growing demand for personalized therapies and ongoing innovations in technologies, we are led to believe that the opportunity for companion diagnostic developers / service providers is likely to witness a sustained growth over the coming years.

Scope of the Report

The “Companion Diagnostics Development Services Market (2nd Edition): Distribution by Type of Service Offered (Feasibility Studies, Assay Development, Analytical Validation, Clinical Validation and Manufacturing), Analytical Technique Used (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry / in situ Hybridization (IHC / ISH), Liquid Biopsy and Others), Therapeutic Areas (Oncological and Non-oncological) and Key Geographies (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape, offering an informed opinion on the likely outsourcing of diagnostic development and manufacturing operations during 2022-2035. It features an in-depth analysis, highlighting the capabilities of various stakeholders involved in the companion diagnostics development value chain.

Amongst other elements, the report includes:

A detailed review of the overall landscape of the companion diagnostics development services market, highlighting the contributions of industry players, along with information on their year of establishment, company size, ownership, geographical location of headquarters, types of services offered, types of analytical techniques used, therapeutic areas assessed and regulatory certifications / accreditations.
A region-wise competitiveness analysis of companies, highlighting the prominent companion diagnostics service providers, by taking into consideration their supplier power (in terms of their experience and company size) and portfolio specifications (in terms of number of services offered, number of analytical techniques used, therapeutic areas assessed, and number of precision medicine related deals signed since 2017).
Elaborate profiles of prominent service providers in this domain. Each company profile includes a brief overview of the company, its financial information (if available), information on its companion diagnostics-related service portfolio, recent developments, and an informed future outlook.
A comprehensive assessment of the current market landscape of companion diagnostics that are either marketed / being developed by various stakeholders, providing information on the assay technique used, target disease indication, therapeutic areas, type of biomarker detected and its chemical nature, type of sample used, regulatory authority involved and expediated review designation (for marketed products), and year of initiation of development (for investigational programs). It also provides details on the diagnostic developers, highlighting their year of establishment, company size, ownership and geographical location of their headquarters.
An analysis of the partnerships and collaborations established for companion diagnostics services during 2017- 2021, featuring a detailed set of analyses based on various parameters, such as the type of partnership, year of partnership, therapeutic areas involved, geographical location of the companies involved and the most active players.
An insightful analysis of companies segregated on the basis of their likelihood to enter into collaborations with companion diagnostics service providers. The chapter features a list of 300+ drug developers sponsoring clinical trials of therapies targeting several disease-specific biomarkers. The players have been shortlisted based on relevant parameters, namely number of biomarker-focused clinical trials sponsored and the time to market their proprietary personalized medicine products.
A detailed analysis of various mergers and acquisitions of companies in this domain, highlighting the trend in the number of companies acquired during the time period between 2017- 2021, based on several relevant parameters, such as year of agreement, type of deal, geographical location of headquarters, company size, key value drivers and acquisition deal multiples (based on revenues). In addition, it presents an ownership change matrix, providing a summary of the involvement of private and public sector entities in this domain.
A qualitative assessment of the current and long-term needs of different stakeholders (drug developers, diagnostic developers, testing laboratories, physicians, payers and patients) involved in this domain. In addition, it highlights key areas of concerns associated with this industry, along with our opinion (based on past and prevalent trends) on how the industry is anticipated to address them over the coming years.
A value chain analysis featuring a discussion on various steps of development operations, namely R&D, clinical assessment of the product, manufacturing and assembly, payer negotiation and marketing activities, of a companion diagnostic, as well as the cost requirements across each of the aforementioned stages.
An assessment of the completed, ongoing and planned biomarker-driven oncology clinical trials sponsored by prominent big pharmaceutical companies, in the last five years. The chapter highlights the key trends associated with these clinical studies across various parameters, such as trial registration year, phase of development, trial sponsors, recruitment status, therapy design, enrolled patient population, popularity of biomarkers, and popularity of target indications.
A case study on various therapies in use with companion diagnostics, providing information on their commercial availability, type of molecule, route of administration, and number of corresponding marketed companion diagnostics products / investigational programs. In addition, it provides details on drug developers, including information on their year of establishment, company size, ownership and geographical location of their headquarters.
A case study on the current market landscape of precision medicine software solutions that offer intelligent insights to diagnostic developers, service providers, patients and healthcare experts, for making informed decisions. The chapter features information on the type of platform utilized, purpose of software solution, type of data processed, therapeutic area, and types of end users. In addition, it presents a list of developers of the software solutions, along with analysis on their year of establishment, company size, ownership and geographical location of headquarters.

One of the key objectives of the report was to estimate the existing market size and the potential future growth opportunities for companion diagnostics development service providers. Based on multiple parameters, such as the service cost of various steps involved in companion diagnostics development and manufacturing, and partnerships inked in the last few years for outsourcing of such operations, we have developed informed estimates on the evolution of the market for the time period 2022- 2035. Our year-wise projections of the current and forecasted opportunity have further been segmented across key services offered (feasibility studies, assay development, analytical validation, clinical validation and manufacturing), analytical techniques used (NGS, PCR, IHC-ISH, liquid biopsy and Others), therapeutic areas (oncological and non-oncological), and key geographical locations (North America, Europe and Asia- Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were influenced by discussions held with several key players in this domain.

The report features detailed transcripts of interviews held with the following industry stakeholders:

Mike Klein (Chief Executive Officer, Genomenon)
Mark Kiel (Founder and Chief Scientific Officer, Genomenon)
Candace Chapman (Vice President of Marketing, Genomenon)
Anton Iliuk (President and Chief Technology Officer, Tymora Analytical Operations)
Paul Kortschak (Former Senior Vice President, Novodiax)
Pablo Ortiz (Chief Executive officer, OWL Metabolomics)
Lawrence M. Weiss (Former Chief Scientific Officer, NeoGenomics Laboratories)

Key Questions Answered

Who are the leading players offering services for the development of companion diagnostics?
What are the key geographies where companion diagnostics development service providers are located?
Which analytical techniques are leveraged by the service providers engaged in this domain?
Who are the leading companion diagnostics developers?
Which biomarkers are most commonly targeted by the marketed products / investigational programs?
Which partnership models are commonly adopted by stakeholders offering companion diagnostics development services?
Which drug developers are most likely to partner with the service providers to seek their expertise?
What are the key value drivers of the merger and acquisition activity within this domain?
Which biomarker-focused targeted drugs developed by big pharmaceutical companies are likely to be administered with companion diagnostics?
How is the current and future opportunity likely to be distributed across key market segments?

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Evolution of Personalized Medicines
3.3. Overview of Companion Diagnostics
3.3.1. Development of Companion Diagnostics
3.3.2. Analytical Techniques Used in Companion Diagnostic Tests
3.3.2.1. Immunohistochemistry
3.3.2.2. In situ Hybridization
3.3.2.3. Polymerase Chain Reaction (PCR)
3.3.2.4. DNA Sequencing / Next Generation Sequencing
3.3.2.5. Liquid Biopsy
3.3.2.6. Flow Cytometry
3.3.3. Advantages of Companion Diagnostics
3.4. Applications of Companion Diagnostics across Different Therapeutic Areas
3.4.1. Oncology
3.4.2. Infectious Diseases
3.4.3. Neurological Disorders
3.5. Regulatory Review and Approval Process for Companion Diagnostics
3.6. Existing Challenges
3.7. Key Guidelines for Selecting a Contract Diagnostics Organization (CDO)
3.8. Future Perspectives

4. COMPANION DIAGNOSTICS SERVICE PROVIDERS: MARKET LANDSCAPE

4.1. Chapter Overview
4.2. Companion Diagnostics Service Providers: List of Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Company Ownership
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Type of Service Offered
4.2.6. Analysis by Other Affiliated Services Offered
4.2.7. Analysis by Type of Analytical Technique Used
4.2.8. Analysis by Therapeutic Area
4.2.9. Grid Representation: Analysis by Company Size, Location of Headquarters and Type of Service Offered
4.2.10. Grid Representation: Analysis by Company Size, Location of Headquarters and Type of Analytical Technique Used
4.2.11. Analysis by Regulatory Accreditation / Certification

5. COMPANION DIAGNOSTICS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS

5.1 Chapter Overview
5.2 Methodology
5.3 Assumptions / Key Parameters
5.4 Competitiveness Analysis: Companion Diagnostics Service Providers
5.4.1 Companion Diagnostics Service Providers based in North America
5.4.2 Companion Diagnostics Service Providers based in Europe
5.4.3 Companion Diagnostics Service Providers based in Asia-Pacific and Rest of the World
5.5. Summary of Key Players

6. COMPANION DIAGNOSTICS SERVICE PROVIDERS: COMPANY PROFILES

6.1. Chapter Overview
6.2. Key Players in North America
6.2.1. Geneuity Clinical Research Services
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook
6.2.2. Interpace Biosciences
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Financial Information
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Labcorp (formerly known as Covance)
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Financial Information
6.2.3.4. Recent Developments and Future Outlook
6.2.4. Quest Diagnostics
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Financial Information
6.2.4.4. Recent Developments and Future Outlook
6.2.5. Q² Solutions
6.2.5.1. Company Overview
6.2.5.2. Service Portfolio
6.2.5.3. Financial Information
6.2.5.4. Recent Developments and Future Outlook
6.2.6. ResearchDx
6.2.6.1. Company Overview
6.2.6.2. Service Portfolio
6.2.6.3. Recent Developments and Future Outlook
6.3. Key Players in Europe
6.3.1. Almac Diagnostic Services
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Financial Information
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Biocartis
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Financial Information
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Cerba Research
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Recent Developments and Future Outlook
6.3.4. Eurofins
6.3.4.1. Company Overview
6.3.4.2. Service Portfolio
6.3.4.3. Financial Information
6.3.4.4. Recent Developments and Future Outlook
6.3.5. MLM Medical Labs
6.3.5.1. Company Overview
6.3.5.2. Service Portfolio
6.3.5.3. Recent Developments and Future Outlook
6.3.6. QIAGEN
6.3.6.1. Company Overview
6.3.6.2. Service Portfolio
6.3.6.3. Financial Information
6.3.6.4. Recent Developments and Future Outlook
6.4. Key Players in Asia-Pacific and Rest of the World
6.4.1. BGI Genomics
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Recent Developments and Future Outlook
6.4.2. MEDx (Suzhou) Translational Medicine (formerly known as QIAGEN (Suzhou) Translational Medicine)
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Recent Developments and Future Outlook
6.4.3. MEDICAL & BIOLOGICAL LABORATORIES (MBL)
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Recent Developments and Future Outlook
6.4.4. Novogene
6.4.4.1. Company Overview
6.4.4.2. Service Portfolio
6.4.4.3. Recent Developments and Future Outlook

7. COMPANION DIAGNOSTICS: MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Companion Diagnostics: List of Marketed Products / Investigational Programs
7.2.1. Analysis by Assay Technique Used
7.2.2. Analysis by Target Disease Indication
7.2.3. Analysis by Therapeutic Area
7.2.4. Analysis by Type of Biomarker Detected
7.2.5. Analysis by Chemical Nature of Biomarker
7.2.6. Analysis by Type of Sample Used
7.2.7. Analysis by Commercial Availability and Therapeutic Area
7.2.8. Investigational Programs: Analysis by Year of Initiation of Development
7.2.9. Marketed Products: Analysis by Year of Approval
7.2.10. Marketed Products: Analysis by Regulatory Authority Involved
7.2.11. Marketed Products: Analysis by Year of Approval and Regulatory Authority Involved
7.2.12. Marketed Products: Analysis by Expediated Review Designation and Type of Biomarker
7.2.13. Heat Map Representation: Analysis by Target Disease Indication and Assay Technique Used
7.3. Companion Diagnostic Devices: List of Developers
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Company Ownership
7.3.4. Analysis by Location of Headquarters
7.3.5. Most Active Players: Analysis by Number of Marketed Products and Investigational Programs
7.3.6. Most Active Players: Analysis by Number of Marketed Products
7.3.7. Most Active Players: Analysis by Number of Target Disease Indications

8. PARTNERSHIPS AND COLLABORATIONS

8.1. Chapter Overview
8.2. Partnership Models
8.3. List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Partner
8.3.4. Analysis by Year of Partnership and Type of Partner
8.3.5. Analysis by Type of Partnership and Type of Partner
8.3.6. Analysis by Therapeutic Area
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Regional Analysis
8.3.9. Intercontinental and Intracontinental Agreements

9. LIKELY PARTNER ANALYSIS

9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Scoring Criteria and Key Assumptions
9.4. Likely Partners for Companion Diagnostics Service Providers: Alzheimer’s Disease
9.4.1. Potential Strategic Partners for Initiatives on Amyloid Beta Biomarker
9.4.1.1. Companies Working on the Amyloid Beta Biomarker
9.4.1.2. World Map Representation: Amyloid Beta Biomarker Focused Clinical Trials
9.4.2. Potential Strategic Partners for Initiatives on Tau Biomarker
9.4.2.1. Companies Working on the Tau Biomarker
9.4.2.2. World Map Representation: Tau Biomarker Focused Clinical Trials
9.5. Likely Partners for Companion Diagnostics Service Providers: Breast Cancer
9.5.1. Potential Strategic Partners for Initiatives on BRCA Biomarker
9.5.1.1. Companies Working on the BRCA Biomarker
9.5.1.2. World Map Representation: BRCA Biomarker Focused Clinical Trials
9.5.2. Potential Strategic Partners for Initiatives on HER Biomarker
9.5.2.1. Companies Working on the HER Biomarker
9.5.2.2. World Map Representation: HER Biomarker Focused Clinical Trials
9.5.3. Potential Strategic Partners for Initiatives on HR Biomarker
9.5.3.1. Companies Working on the HR Biomarker
9.5.3.2. World Map Representation: HR Biomarker Focused Clinical Trials
9.5.4. Potential Strategic Partners for Initiatives on PD-L1 Biomarker
9.5.4.1. Companies Working on the PD-L1 Biomarker
9.5.4.2. World Map Representation: PD-L1 Biomarker Focused Clinical Trials
9.6. Likely Partners for Companion Diagnostics Service Providers: Colorectal Cancer
9.6.1. Potential Strategic Partners for Initiatives on BRAF Biomarker
9.6.1.1. Companies Working on the BRAF Biomarker
9.6.1.2. World Map Representation: BRAF Biomarker Focused Clinical Trials
9.6.2. Potential Strategic Partners for Initiatives on EGFR Biomarker
9.6.2.1. Companies Working on the EGFR Biomarker
9.6.2.2. World Map Representation: EGFR Biomarker Focused Clinical Trials
9.6.3. Potential Strategic Partners for Initiatives on KRAS Biomarker
9.6.3.1. Companies Working on the KRAS Biomarker
9.6.3.2. World Map Representation: KRAS Biomarker Focused Clinical Trials
9.6.4. Potential Strategic Partners for Initiatives on MSI Biomarker
9.6.4.1. Companies Working on the MSI Biomarker
9.6.4.2. World Map Representation: MSI Biomarker Focused Clinical Trials
9.6.5. Potential Strategic Partners for Initiatives on NRAS Biomarker
9.6.5.1. Companies Working on the NRAS Biomarker
9.6.5.2. World Map Representation: NRAS Biomarker Focused Clinical Trials
9.7. Likely Partners for Companion Diagnostic Service Providers: HIV
9.7.1. Potential Strategic Partners for Initiatives on CCR5 Biomarker
9.7.1.1. Companies Working on the CCR5 Biomarker
9.7.1.2. World Map Representation: CCR5 Biomarker Focused Clinical Trials
9.8. Likely Partners for Companion Diagnostics Service Providers: Lung Cancer
9.8.1. Potential Strategic Partners for Initiatives on ALK Biomarker
9.8.1.1. Companies Working on the ALK Biomarker
9.8.1.2. World Map Representation: ALK Biomarker Focused Clinical Trials
9.8.2. Potential Strategic Partners for Initiatives on EGFR Biomarker
9.8.2.1. Companies Working on the EGFR Biomarker
9.8.2.2. World Map Representation: EGFR Biomarker Focused Clinical Trials
9.8.3. Potential Strategic Partners for Initiatives on PD-L1 Biomarker
9.8.3.1. Companies Working on the PD-L1 Biomarker
9.8.3.2. World Map Representation: PD-L1 Biomarker Focused Clinical Trials
9.8.4. Potential Strategic Partners for Initiatives on RET Biomarker
9.8.4.1. Companies Working on the RET Biomarker
9.8.4.2. World Map Representation: RET Biomarker Focused Clinical Trials
9.8.5. Potential Strategic Partners for Initiatives on ROS Biomarker
9.8.5.1. Companies Working on the ROS Biomarker
9.8.5.2. World Map Representation: ROS Biomarker Focused Clinical Trials
9.9. Likely Partners for Companion Diagnostics Service Providers: NASH / NAFLD
9.9.1. Potential Strategic Partners for Initiatives on AST Biomarker
9.9.1.1. Companies Working on the AST Biomarker
9.9.1.2. World Map Representation: AST Biomarker Focused Clinical Trials
9.10. Likely Partners for Companion Diagnostics Service Providers: Ovarian Cancer
9.10.1. Potential Strategic Partners for Initiatives on BRCA Biomarker
9.10.1.1. Companies Working on the BRCA Biomarker
9.10.1.2. World Map Representation: BRCA Biomarker Focused Clinical Trials
9.10.2. Potential Strategic Partners for Initiatives on CA-125 Biomarker
9.10.2.1. Companies Working on the CA-125 Biomarker
9.10.2.2. World Map Representation: CA-125 Biomarker Focused Clinical Trials
9.11. Likely Partners for Companion Diagnostics Service Providers: Prostate Cancer
9.11.1. Potential Strategic Partners for Initiatives on AR-V7 Biomarker
9.11.1.1. Companies Working on the AR-V7 Biomarker
9.11.1.2. World Map Representation: AR-V7 Biomarker Focused Clinical Trials

10. MERGERS AND ACQUISITONS

10.1. Chapter Overview
10.2. Merger and Acquisition Models
10.3. List of Mergers and Acquisitions
10.3.1. Analysis by Type of Deal
10.3.2. Analysis by Year of Deal
10.3.3. Regional Analysis
10.3.3.1. Continent-wise Distribution
10.3.3.2. Intercontinental and Intracontinental Deals
10.3.3.3. Country-wise Distribution
10.3.4. Analysis by Company Size
10.3.5. Ownership Change Matrix
10.3.6. Analysis by Key Value Drivers
10.3.7. Valuation Analysis: Acquisition Deal Multiples
10.3.8. Key Players: Analysis by Number of Deals

11. STAKEHOLDER NEEDS ANALYSIS

11.1. Chapter Overview
11.2. Companion Diagnostics: Needs of Different Stakeholders
11.3. Comparison of Needs of Various Stakeholders
11.3.1. Needs of Drug Developers
11.3.2. Needs of Companion Diagnostics Developers
11.3.3. Needs of Regulatory Authorities
11.3.4. Needs of Testing Laboratories
11.3.5. Needs of Payers / Insurance Providers
11.3.6. Needs of Physicians
11.3.7. Needs of Patients

12. VALUE CHAIN ANALYSIS

12.1. Chapter Overview
12.2. Companion Diagnostics Value Chain: Cost Distribution
12.2.1. Research and Product Development
12.2.2. Manufacturing and Assembly
12.2.3. Clinical Trials, FDA Approval and Other Administrative Tasks
12.2.4. Payer Negotiation and KOL Engagement
12.2.5. Marketing and Sales
12.3. Companion Diagnostics Development Operations: Key Cost Contributors
12.4. Companion Diagnostics Co-Development Operations: Key Cost Contributors

13. CLINICAL RESEARCH ON CANCER BIOMARKERS: BIG PHARMA PERSPECTIVE

13.1. Chapter Overview
13.2. Methodology
13.3. Big Pharma Sponsored Biomarker Focused Clinical Trials: List of Likely Drug Candidates for IVD Developers
13.4. Clinical Trial Analysis
13.4.1. Analysis of Trials by Trial Registration Year
13.4.2. Analysis of Trials by Phase of Development
13.4.3. Analysis of Trials by Sponsor
13.4.4. Analysis of Trials by Recruitment Status
13.4.5. Analysis of Trials by Therapy Design
13.4.6. Analysis of Trials by Geography
13.4.7. Analysis of Trials by Enrolled Patient Population
13.4.8. Analysis of Trials by Popularity of Biomarkers
13.4.8.1. Most Popular Biomarkers
13.4.8.2. Moderately Popular Biomarkers
13.4.8.3. Less Popular / Preliminary Stage Biomarkers
13.4.8.4. Other Emerging Biomarkers: Word Cloud
13.4.8.5. Analysis of Trials of Most Popular Biomarkers by Trial Registration Year
13.4.8.6. Analysis of Trials of Moderately Popular Biomarkers by Trial Registration Year
13.4.8.7. Analysis of Trials of Less Popular Biomarkers by Trial Registration Year
13.4.8.8. Analysis of Trials of Most Popular Biomarkers by Phase of Development
13.4.8.9. Analysis of Trials of Moderately Popular Biomarkers by Phase of Development
13.4.8.10. Analysis of Trials of Less Popular and Other Biomarkers by Phase of Development
13.4.8.11. Analysis of Trials of Most Popular Biomarkers by Sponsors
13.4.8.12. Analysis of Trials of Moderately Popular Biomarkers by Sponsors
13.4.8.13. Analysis of Trials of Less Popular and Other Biomarkers by Sponsors
13.4.9. Analysis of Trials by Popularity of Indications
13.4.9.1. Most Popular Indications
13.4.9.2. Moderately Popular Indications
13.4.9.3 Less Popular and Other Indications
13.4.9.4. Other Emerging Indications: Word Cloud
13.4.9.5. Analysis of Trials of Most Popular Indications by Trial Registration Year
13.4.9.6. Analysis of Trials of Moderately Popular Indications by Trial Registration Year
13.4.9.7. Analysis of Trials of Less Popular / Preliminary Stage Indications by Trial Registration Year
13.4.9.8. Analysis of Trials of Most Popular Indications by Phase of Development
13.4.9.9. Analysis of Trials of Moderately Popular Indications by Phase of Development
13.4.9.10. Analysis of Trials of Less Popular / Preliminary Stage Indications by Phase of Development
13.4.9.11. Analysis of Trials of Less Popular / Preliminary Stage Indications by Trial Registration Year
13.4.9.12. Analysis of Trials of Most Popular Indications by Sponsor
13.4.9.13. Analysis of Trials of Moderately Popular Indications by Sponsor
13.4.9.14. Analysis of Trials of Less Popular / Preliminary Stage Indications by Sponsor
13.5. Clinical Trials Summary

14. CASE STUDY ON BIOMARKER-DRIVEN TARGETED THERAPIES IN USE WITH COMPANION DIAGNOSTICS

14.1. Chapter Overview
14.2. Biomarker-Driven Targeted Therapies: Pipeline Review
14.2.1. Analysis by Commercial Availability
14.2.2. Analysis by Type of Molecule
14.2.3. Analysis by Commercial Availability and Type of Molecule
14.2.4. Analysis by Route of Administration
14.2.5. Leading Biomarker-Driven Targeted Therapies: Analysis by Number of Companion Diagnostic Products / Programs
14.3. Biomarker-Driven Targeted Therapies: Developer Landscape
14.3.1. Analysis by Year of Establishment
14.3.2. Analysis by Company Size
14.3.3. Analysis by Company Ownership
14.3.4. Analysis by Location of Headquarters
14.3.5. Leading Players: Analysis by Number of Drugs
14.4. Heat Map Representation: Analysis by Company Size, Location of Headquarters and Commercial Availability of Drug

15. CASE STUDY ON PRECISION MEDICINE SOFTWARE SOLUTIONS

15.1. Chapter Overview
15.2. Precision Medicine Software Solutions: List of Products
15.2.1. Analysis by Type of Platform
15.2.2. Analysis by Purpose of Software Applications
15.2.3. Analysis by Type of Data Handled
15.2.4. Analysis by Therapeutic Area
15.2.5. Analysis by Type of End User
15.3. Precision Medicine Software Solutions: List of Developers
15.3.1. Analysis by Year of Establishment
15.3.2. Analysis by Company Size
15.3.3. Analysis by Location of Headquarters

16. COMPANION DIAGNOSTICS SERVICE PROVIDERS: MARKET FORECAST AND OPPORTUNITY ANALYSIS

16.1 Chapter Overview
16.2. Key Assumptions and Forecast Methodology
16.3. Global Companion Diagnostics Services Market, 2022-2035
16.3.1. Global Companion Diagnostics Services Market: Distribution by Type of Service Offered, 2022-2035
16.3.2. Global Companion Diagnostics Services Market: Distribution by Type of Analytical Technique Used, 2022-2035
16.3.3. Global Companion Diagnostics Services Market: Distribution by Therapeutic Area, 2022-2035
16.3.4. Global Companion Diagnostics Services Market: Distribution by Region, 2022-2035
16.4. Companion Diagnostics Services Market in North America, 2022-2035
16.4.1. Companion Diagnostics Services Market in North America: Distribution by Type of Service Offered, 2022-2035
16.4.2. Companion Diagnostics Services Market in North America: Distribution by Type of Analytical Technique Used, 2022-2035
16.4.3. Companion Diagnostics Services Market in North America: Distribution by Therapeutic Area, 2022-2035
16.5. Companion Diagnostics Services Market in Europe, 2022-2035
16.5.1. Companion Diagnostics Services Market in Europe: Distribution by Type of Service Offered, 2022-2035
16.5.2. Companion Diagnostics Services Market in Europe: Distribution by Type of Analytical Technique Used, 2022-2035
16.5.3. Companion Diagnostics Services Market in Europe: Distribution by Therapeutic Area, 2022-2035
16.6. Companion Diagnostics Services Market in Asia-Pacific and Rest of the World, 2022-2035
16.6.1. Companion Diagnostics Services Market in Asia-Pacific and Rest of the World: Distribution by Type of Service Offered, 2022-2035
16.6.2. Companion Diagnostics Services Market in Asia-Pacific and Rest of the World: Distribution by Type of Analytical Technique Used, 2022-2035
16.6.3. Companion Diagnostics Services Market in Asia-Pacific and Rest of the World: Distribution by Therapeutic Area, 2022-2035

17. EXECUTIVE INSIGHTS

17.1. Chapter Overview
17.2. Genomenon
17.2.1. Company Snapshot
17.2.2. Interview Transcript: Mike Klein, Chief Executive Officer; Mark Kiel, Founder and Chief Scientific Officer; and Candace Chapman, Vice President of Marketing
17.3. Tymora Analytical Operations
17.3.1. Company Snapshot
17.3.2. Interview Transcript: Anton Iliuk, President and Chief Technology Officer
17.4. Novodiax
17.4.1. Company Snapshot
17.4.2. Interview Transcript: Paul Kortschak, Former Senior Vice President
17.5. OWL Metabolomics
17.5.1. Company Snapshot
17.5.2. Interview Transcript: Pablo Ortiz, Chief Executive Officer
17.6. NeoGenomics Laboratories
17.6.1. Company Snapshot
17.6.2. Interview Transcript: Lawrence M. Weiss, Former Chief Scientific Officer

18. CONCLUDING REMARKS

18.1. Chapter Overview
18.2. Key Takeaways

19. APPENDIX 1: TABULATED DATA20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Companion Diagnostics: Role in Clinical Trials
Figure 3.2 Advantages of Companion Diagnostics
Figure 3.3 Failure Rates: Distribution by Type of Drug Class
Figure 3.4 Challenges Associated with the Development of Companion Diagnostics
Figure 3.5 Key Considerations for Selecting a CDO Partner
Figure 4.1 Companion Diagnostics Service Providers: Distribution by Year of Establishment
Figure 4.2 Companion Diagnostics Service Providers: Distribution by Company Size
Figure 4.3 Companion Diagnostics Service Providers: Distribution by Company Ownership
Figure 4.4 Companion Diagnostics Service Providers: Distribution by Location of Headquarters
Figure 4.5 World Map Representation: Analysis by Geography
Figure 4.6 Companion Diagnostics Service Providers: Distribution by Type of Service Offered
Figure 4.7 Companion Diagnostics Service Providers: Distribution by Other Affiliated Services Offered
Figure 4.8 Companion Diagnostics Service Providers: Distribution by Type of Analytical Technique Used
Figure 4.9 Companion Diagnostics Service Providers: Distribution by Therapeutic Area
Figure 4.10 Grid Representation: Distribution by Company Size, Location of Headquarters and Type of Service Offered
Figure 4.11 Grid Representation: Distribution by Company Size, Location of Headquarters and Analytical Technique Used
Figure 4.12 Companion Diagnostics Service Providers: Distribution by Regulatory Accreditation / Certification
Figure 5.1 Competitiveness Analysis: Companion Diagnostics Service Providers in North America
Figure 5.2 Competitiveness Analysis: Companion Diagnostics Service Providers in Europe
Figure 5.3 Competitiveness Analysis: Companion Diagnostics Service Providers in Asia-Pacific and Rest of the World
Figure 5.4 Competitiveness Analysis of Companion Diagnostics Service Providers: Competitiveness Score of Top Service Providers
Figure 6.1 Interpace Biosciences: Annual Revenues, FY 2016-Q3 2021 (USD Million)
Figure 6.2 Labcorp Drug Development: Annual Revenues, FY 2016-2021 (USD Billion)
Figure 6.3 Quest Diagnostics: Annual Revenues, FY 2016-2021 (USD Billion)
Figure 6.4 Q² Solutions: Annual Revenues, FY 2016-2021 (USD Million)
Figure 6.5 Almac Group Diagnostics: Annual Revenues, FY 2016-2021 (GBP Million)
Figure 6.6 Biocartis: Annual Revenues, FY 2016-H1 2021 (EUR Billion)
Figure 6.7 Eurofins: Annual Revenues, FY 2016-H1 2021 (EUR Billion)
Figure 6.8 QIAGEN: Annual Revenues, FY 2016-2021 (USD Billion)
Figure 7.1 Companion Diagnostics: Distribution by Assay Technique Used
Figure 7.23 Companion Diagnostics: Distribution by Target Disease Indication
Figure 7.3 Companion Diagnostics: Distribution by Therapeutic Area
Figure 7.4 Companion Diagnostics: Distribution by Type of Biomarker Detected
Figure 7.5 Companion Diagnostics: Distribution by Chemical Nature of Biomarker
Figure 7.6 Companion Diagnostics: Distribution by Type of Sample Used
Figure 7.7 Companion Diagnostics: Distribution by Commercial Availability and Therapeutic Area
Figure 7.8 Companion Diagnostics: Distribution by Year of Initiation of Development of Investigational Programs
Figure 7.9 Companion Diagnostics: Distribution by Year of Approval of Marketed Products
Figure 7.10 Companion Diagnostics: Distribution by Regulatory Authority Involved in the Approval of Marketed Products
Figure 7.11 Companion Diagnostics: Distribution by Expediated Review Designation and Type of Biomarker
Figure 7.12 Heat Map Representation: Distribution by Assay Technique Used and Target Disease Indication
Figure 7.13 Companion Diagnostics Developers: Distribution by Year of Establishment
Figure 7.14 Companion Diagnostics Developers: Distribution by Company Size
Figure 7.15 Companion Diagnostics Developers: Distribution by Company Ownership
Figure 7.16 Companion Diagnostics Developers: Distribution by Location of Headquarters
Figure 7.17 World Map Representation: Distribution by Geography
Figure 7.18 Most Active Players: Distribution by Number of Marketed Products and Investigational Programs
Figure 7.19 Most Active Players: Distribution by Number of Marketed Products
Figure 7.20 Most Active Players: Distribution by Number of Target Disease Indications
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.7 Most Active Players: Distribution by Number of Partnerships
Figure 8.8 Partnerships and Collaborations: Regional Distribution
Figure 8.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 World Map Representation: Regional Distribution of Amyloid Beta Biomarker Focused Clinical Trials
Figure 9.2 World Map Representation: Regional Distribution of Tau Biomarker Focused Clinical Trials
Figure 9.3 World Map Representation: Regional Distribution of BRCA Biomarker Focused Clinical Trials
Figure 9.4 World Map Representation: Regional Distribution of HER Biomarker Focused Clinical Trials
Figure 9.5 World Map Representation: Regional Distribution of HR Biomarker Focused Clinical Trials
Figure 9.6 World Map Representation: Regional Distribution of PD-L1 Biomarker Focused Clinical Trials
Figure 9.7 World Map Representation: Regional Distribution of BRAF Biomarker Focused Clinical Trials
Figure 9.8 World Map Representation: Regional Distribution of EGFR Biomarker Focused Clinical Trials
Figure 9.9 World Map Representation: Regional Distribution of KRAS Biomarker Focused Clinical Trials
Figure 9.10 World Map Representation: Regional Distribution of MSI Biomarker Focused Clinical Trials
Figure 9.11 World Map Representation: Regional Distribution of NRAS Biomarker Focused Clinical Trials
Figure 9.12 World Map Representation: Regional Distribution of CCR5 Biomarker Focused Clinical Trials
Figure 9.13 World Map Representation: Regional Distribution of ALK Biomarker Focused Clinical Trials
Figure 9.14 World Map Representation: Regional Distribution of EGFR Biomarker Focused Clinical Trials
Figure 9.15 World Map Representation: Regional Distribution of PD-L1 Biomarker Focused Clinical Trials
Figure 9.16 World Map Representation: Regional Distribution of RET Biomarker Focused Clinical Trials
Figure 9.17 World Map Representation: Regional Distribution of ROS Biomarker Focused Clinical Trials
Figure 9.18 World Map Representation: Regional Distribution of AST Biomarker Focused Clinical Trials
Figure 9.19 World Map Representation: Regional Distribution of BRCA Biomarker Focused Clinical Trials
Figure 9.20 World Map Representation: Regional Distribution of CA-125 Biomarker Focused Clinical Trials
Figure 9.21 World Map Representation: Regional Distribution of AR-V7 Biomarker Focused Clinical Trials
Figure 10.1 Mergers and Acquisitions: Distribution by Type of Deal
Figure 10.2 Mergers and Acquisitions: Distribution by Year of Deal
Figure 10.3 Mergers and Acquisitions: Regional Distribution
Figure 10.4 Mergers and Acquisitions: Continent-wise Distribution
Figure 10.5 Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Figure 10.6 Mergers and Acquisitions: Country-wise Distribution
Figure 10.7 Mergers and Acquisitions: Distribution by Company Size
Figure 10.8 Mergers and Acquisitions: Ownership Change Matrix
Figure 10.9 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 10.10 Mergers and Acquisitions: Valuation by Acquisition Deal Multiples
Figure 10.11 Key Players: Distribution by Number of Deals
Figure 11.1 Companion Diagnostics: Stakeholder Needs
Figure 11.2 Comparison of Needs of a Drug Developer
Figure 11.3 Comparison of Needs of a Companion Diagnostic Developer
Figure 11.4 Comparison of Needs of a Regulatory Authorities
Figure 11.5 Comparison of Needs of Testing Laboratories
Figure 11.6 Comparison of Needs of Payers / Insurance Providers
Figure 11.7 Comparison of Needs of Physicians
Figure 11.8 Comparison of Needs of Patients
Figure 12.1 Companion Diagnostics Value Chain: Cost Distribution
Figure 12.2 Cost Distribution Across the Companion Diagnostics Value Chain
Figure 12.3 Costs Associated with Research and Product Development
Figure 12.4 Costs Associated with Manufacturing and Assembly
Figure 12.5 Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
Figure 12.6 Costs Associated with Payer Negotiation and KOL Engagement
Figure 12.7 Costs Associated with Marketing and Sales
Figure 13.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 13.2 Clinical Trial Analysis: Distribution by Phase of Development
Figure 13.3 Clinical Trial Analysis: Distribution by Sponsor
Figure 13.4 Clinical Trial Analysis: Distribution by Recruitment Status
Figure 13.5 Clinical Trial Analysis: Distribution by Therapy Design
Figure 13.6 Clinical Trial Analysis: Distribution by Geography
Figure 13.7 Clinical Trial Analysis: Distribution by Enrolled Patient Population
Figure 13.8 Clinical Trial Analysis: Distribution by Most Popular Biomarkers
Figure 13.9 Clinical Trial Analysis: Distribution by Moderately Popular Biomarkers
Figure 13.10 Clinical Trial Analysis: Distribution by Less Popular / Preliminary Stage Biomarkers
Figure 13.11 Other Emerging Biomarkers: Word Cloud
Figure 13.12 Clinical Trial Analysis: Distribution of Trials of Most Popular Biomarkers by Trial Registration Year
Figure 13.13 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Biomarkers by Trial Registration Year
Figure 13.14 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Biomarkers by Trial Registration Year
Figure 13.15 Clinical Trial Analysis: Distribution of Trials of Most Popular Biomarkers by Phase of Development
Figure 13.16 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Biomarkers by Phase of Development
Figure 13.17 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Biomarkers by Phase of Development
Figure 13.18 Clinical Trial Analysis: Distribution of Trials of Most Popular Biomarkers by Sponsors
Figure 13.19 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Biomarkers by Sponsors
Figure 13.20 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Biomarkers by Sponsors
Figure 13.21 Clinical Trial Analysis: Distribution of Trials for Most Popular Indications
Figure 13.22 Clinical Trial Analysis: Distribution of Trials for Moderately Popular Indications
Figure 13.23 Clinical Trial Analysis: Distribution of Trials for Less Popular and Other Indications
Figure 13.24 Other Emerging Indications: Word Cloud
Figure 13.25 Clinical Trial Analysis: Distribution of Trials of Most Popular Indications by Trial Registration Year
Figure 13.26 Clinical Trial Analysis: Distribution of Trial of Moderately Popular Indications by Trial Registration Year
Figure 13.27 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Indications by Trial Registration Year
Figure 13.28 Clinical Trial Analysis: Distribution of Trials of Most Popular Indications by Phase of Development
Figure 13.29 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Indications by Phase of Development
Figure 13.30 Clinical Trial Analysis: Distribution of Trials of Less Popular and Emerging Indications by Phase of Development
Figure 13.31 Clinical Trial Analysis: Distribution of Trials of Most Popular Indications by Sponsor
Figure 13.32 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Indications by Sponsor
Figure 13.33 Clinical Trial Analysis: Distribution of Trials of Less Popular and Emerging Indications by Sponsor
Figure 13.34 Clinical Trial Analysis: Distribution of Trials of Lung Cancer by Affiliated Biomarkers
Figure 13.35 Clinical Trials Summary: Distribution of Trials of Breast Cancer by Affiliated Biomarkers
Figure 13.36 Clinical Trials Summary: Distribution of Trials of Lymphoma by Affiliated Biomarkers
Figure 13.37 Clinical Trials Summary: Distribution of Trials of Ovarian Cancer by Affiliated Biomarkers
Figure 13.38 Clinical Trials Summary: Distribution of Trials of Prostate Cancer by Affiliated Biomarkers
Figure 13.39 Clinical Trials Summary: Distribution of Trials of Melanoma by Affiliated Biomarkers
Figure 13.40 Clinical Trials Summary: Distribution of Trials of Colon / Colorectal Cancer by Affiliated Biomarkers
Figure 13.41 Clinical Trials Summary: Distribution of Trials of Head and Neck Cancer by Affiliated Biomarkers
Figure 14.1 Biomarker-Driven Targeted Therapies: Distribution by Commercial Availability
Figure 14.2 Biomarker-Driven Targeted Therapies: Distribution by Type of Molecule
Figure 14.3 Biomarker-Driven Targeted Therapies: Distribution by Commercial Availability and Type of Molecule
Figure 14.4 Biomarker-Driven Targeted Therapies: Distribution by Route of Administration
Figure 14.5 Leading Biomarker-Driven Targeted Therapies: Distribution by Number of Companion Diagnostic Products / Programs
Figure 14.6 Biomarker-Driven Targeted Therapy Developers: Distribution by Year of Establishment
Figure 14.7 Biomarker-Driven Targeted Therapy Developers: Distribution by Company Size
Figure 14.8 Biomarker-Driven Targeted Therapy Developers: Distribution by Company Ownership
Figure 14.9 Biomarker-Driven Targeted Therapy Developers: Distribution by Location of Headquarters
Figure 14.10 Leading Players: Distribution by Number of Biomarker-Driven Targeted Therapies
Figure 14.11 Heat Map Representation: Distribution by Company Size, Location of Headquarters and Commercial Availability of Therapy
Figure 15.1 Precision Medicine Software Solutions: Distribution by Type of Platform
Figure 15.2 Precision Medicine Software Solutions: Distribution by Purpose of Software Applications
Figure 15.3 Precision Medicine Software Solutions: Distribution by Type of Data Handled
Figure 15.4 Precision Medicine Software Solutions: Distribution by Therapeutic Area
Figure 15.5 Precision Medicine Software Solutions: Distribution by Type of End User
Figure 15.6 Precision Medicine Software Solution Developers: Distribution by Year of Establishment
Figure 15.7 Precision Medicine Software Solution Developers: Distribution by Company Size
Figure 15.8 Precision Medicine Software Solution Developers: Distribution by Location of Headquarters
Figure 15.9 World Map Representation: Distribution by Geography
Figure 16.1 Global Companion Diagnostics Development Services Market, 2022-2035 (USD Million)
Figure 16.2 Global Companion Diagnostics Development Services Market: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Figure 16.3 Global Companion Diagnostics Development Services Market: Distribution by Type of Analytical Technique Used, 2022-2035 (USD Million)
Figure 16.4 Global Companion Diagnostics Development Services Market: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 16.5 Global Companion Diagnostics Development Services Market: Distribution by Region, 2022-2035 (USD Million)
Figure 16.6 Companion Diagnostics Development Services Market in North America, 2022-2035 (USD Million)
Figure 16.7 Companion Diagnostics Development Services Market in North America: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Figure 16.8 Companion Diagnostics Development Services Market in North America: Distribution by Type of Analytical Technique Used, 2022-2035 (USD Million)
Figure 16.9 Companion Diagnostics Development Services Market in North America: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 16.7 Companion Diagnostics Development Services Market in Europe, 2022-2035 (USD Million)
Figure 16.8 Companion Diagnostics Development Services Market in Europe: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Figure 16.9 Companion Diagnostics Development Services Market in Europe: Distribution by Type of Analytical Technique Used, 2022-2035 (USD Million)
Figure 16.10 Companion Diagnostics Development Services Market in Europe: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 16.11 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Figure 16.12 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of the World: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Figure 16.13 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of The World: Distribution by Type of Analytical Technique Used, 2022-2035 (USD Million)
Figure 16.14 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of the World: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Figure 18.1 Concluding Remarks: Overall Market Landscape of Companion Diagnostics Service Providers
Figure 18.2 Concluding Remarks: Overall Market Landscape of Companion Diagnostics
Figure 18.3 Concluding Remarks: Partnerships and Collaborations
Figure 18.4 Concluding Remarks: Likely Partners
Figure 18.5 Concluding Remarks: Mergers and Acquisitions
Figure 18.6 Concluding Remarks: Big Pharma Initiatives
Figure 18.7 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 4.1 Companion Diagnostics Service Providers: List of Players
Table 4.2 Companion Diagnostics Service Providers: Information on Type of Service(s) Offered
Table 4.3 Companion Diagnostics Service Providers: Information on Type of Analytical Technique(s) Used
Table 4.4 Companion Diagnostics Service Providers: Information on Therapeutic Area(s)
Table 4.5 Companion Diagnostics Service Providers: Additional Information on Regulatory Certification(s) / Accreditation(s)
Table 6.1 Companion Diagnostics Service Providers: List of Companies Profiled
Table 6.2 Geneuity Clinical Research Services: Company Snapshot
Table 6.3 Geneuity Clinical Research Services: Companion Diagnostics Service Portfolio
Table 6.4 Geneuity Clinical Research Services: Recent Developments and Future Outlook
Table 6.5 Interpace Biosciences: Company Snapshot
Table 6.6 Interpace Biosciences: Companion Diagnostics Service Portfolio
Table 6.7 Interpace Biosciences: Recent Developments and Future Outlook
Table 6.8 Labcorp: Company Snapshot
Table 6.9 Labcorp: Companion Diagnostics Service Portfolio
Table 6.10 Labcorp: Recent Developments and Future Outlook
Table 6.11 ResearchDx: Company Snapshot
Table 6.12 ResearchDx: Companion Diagnostics Service Portfolio
Table 6.13 ResearchDx: Recent Developments and Future Outlook
Table 6.14 Quest Diagnostics: Company Snapshot
Table 6.15 Quest Diagnostics: Companion Diagnostics Service Portfolio
Table 6.16 Quest Diagnostics: Recent Developments and Future Outlook
Table 6.17 Q² Solutions: Company Snapshot
Table 6.18 Q² Solutions: Companion Diagnostics Service Portfolio
Table 6.19 Q² Solutions: Recent Developments and Future Outlook
Table 6.20 Almac Diagnostic Services: Company Snapshot
Table 6.21 Almac Diagnostic Services: Companion Diagnostics Service Portfolio
Table 6.22 Almac Diagnostic Services: Recent Developments and Future Outlook
Table 6.23 Biocartis: Company Snapshot
Table 6.24 Biocartis: Companion Diagnostics Service Portfolio
Table 6.25 Biocartis: Recent Developments and Future Outlook
Table 6.26 Cerba Research: Company Snapshot
Table 6.27 Cerba Research: Companion Diagnostics Service Portfolio
Table 6.28 Cerba Research: Recent Developments and Future Outlook
Table 6.29 Eurofins: Company Snapshot
Table 6.30 Eurofins: Companion Diagnostics Service Portfolio
Table 6.31 Eurofins: Recent Developments and Future Outlook
Table 6.32 MLM Medical Labs: Company Snapshot
Table 6.33 MLM Medical Labs: Companion Diagnostics Service Portfolio
Table 6.34 MLM Medical Labs: Recent Developments and Future Outlook
Table 6.35 QIAGEN: Company Snapshot
Table 6.36 QIAGEN: Companion Diagnostics Service Portfolio
Table 6.37 QIAGEN: Recent Developments and Future Outlook
Table 6.38 BGI Genomics: Company Snapshot
Table 6.39 BGI Genomics: Companion Diagnostics Service Portfolio
Table 6.40 BGI Genomics: Recent Developments and Future Outlook
Table 6.41 MEDx (Suzhou) Translational Medicine: Company Snapshot
Table 6.42 MEDx (Suzhou) Translational Medicine: Companion Diagnostics Service Portfolio
Table 6.43 MEDx (Suzhou) Translational Medicine: Recent Developments and Future Outlook
Table 6.44 MEDICAL & BIOLOGICAL LABORATORIES (MBL): Company Snapshot
Table 6.45 MEDICAL & BIOLOGICAL LABORATORIES (MBL): Companion Diagnostics Service Portfolio
Table 6.46 MEDICAL & BIOLOGICAL LABORATORIES (MBL): Recent Developments and Future Outlook
Table 6.47 Novogene: Company Snapshot
Table 6.48 Novogene: Companion Diagnostics Service Portfolio
Table 6.49 Novogene: Recent Developments and Future Outlook
Table 8.1 Companion Diagnostics Service Providers: List of Partnerships and Collaborations, 2017-2021
Table 9.1 Companies / Organizations Working on the Amyloid Beta Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.2 Companies / Organizations Working on the Tau Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.3 Companies / Organizations Working on the BRCA Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.4 Companies / Organizations Working on the HER Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.5 Companies / Organizations Working on the HR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.6 Companies / Organizations Working on the PD-L1 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.7 Companies / Organizations Working on the BRAF Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.8 Companies / Organizations Working on the EGFR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.9 Companies / Organizations Working on the KRAS Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.10 Companies / Organizations Working on the MSI Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.11 Companies / Organizations Working on the NRAS Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.12 Companies / Organizations Working on the CCR5 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.13 Companies / Organizations Working on the ALK Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.14 Companies / Organizations Working on the EGFR Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.15 Companies / Organizations Working on the PD-L1 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.16 Companies / Organizations Working on the RET Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.17 Companies / Organizations Working on the ROS Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.18 Companies / Organizations Working on the AST Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.19 Companies / Organizations Working on the BRCA Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.20 Companies / Organizations Working on the CA-125 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 9.21 Companies / Organizations Working on the AR-V7 Biomarker: Potential Partners for Companion Diagnostic Service Providers
Table 10.1 Companion Diagnostics Service Providers: Mergers and Acquisitions, 2017-2021
Table 11.1 Comparison of Needs of Stakeholders
Table 13.1 List of Likely Drug Candidates / Potential Collaborators for Companion Diagnostic Developers
Table 13.2 List of Biomarkers across Moderately Popular Indications
Table 13.3 List of Biomarkers across Emerging Indications
Table 14.1 Biomarker Driven Targeted Therapies: Information on Commercial Availability, Type of Molecule and Route of Administration
Table 14.2 Biomarker Driven Targeted Therapies: List of Developers
Table 15.1 Precision Medicine Software Solutions: Information on Type of Platform, Status of Development and Compliance
Table 15.2 Precision Medicine Software Solutions: Information on Purpose of Software, Type of Data Handled, Therapeutic Area and End User
Table 15.3 Precision Medicine Software Solution Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 17.1 Genomenon: Company Snapshot
Table 17.2 Tymora Analytical Operations: Company Snapshot
Table 17.3 Novodiax: Company Snapshot
Table 17.4 OWL Metabolomics: Company Snapshot
Table 17.5 NeoGenomics Laboratories: Company Snapshot
Table 19.1 Companion Diagnostics Service Providers: Distribution by Year of Establishment
Table 19.2 Companion Diagnostics Service Providers: Distribution by Company Size
Table 19.3 Companion Diagnostics Service Providers: Distribution by Company Ownership
Table 19.4 Companion Diagnostics Service Providers: Distribution by Location of Headquarters
Table 19.5 World Map Representation: Distribution by Geography
Table 19.6 Companion Diagnostics Service Providers: Distribution by Service Offered
Table 19.7 Companion Diagnostics Service Providers: Distribution by Other Affiliated Service Offered
Table 19.8 Companion Diagnostics Service Providers: Distribution by Type of Analytical Technique
Table 19.9 Companion Diagnostics Service Providers: Distribution by Therapeutic Area
Table 19.10 Companion Diagnostics Service Providers: Distribution by Regulatory Accreditation / Certification
Table 19.11 Interpace Biosciences: Annual Revenues, FY 2016-Q3 2021 (USD Million)
Table 19.12 Labcorp Drug Development: Annual Revenues, FY 2016-2021 (USD Billion)
Table 19.13 Quest Diagnostics: Annual Revenues, FY 2016-2021 (USD Billion)
Table 19.14 Q² Solutions: Annual Revenues, FY 2016-2021 (USD Million)
Table 19.15 Almac Group Diagnostics: Annual Revenues, FY 2016-2021 (GBP Million)
Table 19.16 Biocartis: Annual Revenues, FY 2016-H1 2021 (EUR Billion)
Table 19.17 Eurofins: Annual Revenues, FY 2016-H1 2021 (EUR Billion)
Table 19.18 QIAGEN: Annual Revenues, FY 2016-2021 (USD Billion)
Table 19.19 Companion Diagnostics: Distribution by Assay Technique Used
Table 19.20 Companion Diagnostics: Distribution by Target Disease Indication
Table 19.21 Companion Diagnostics: Distribution by Therapeutic Area
Table 19.22 Companion Diagnostics: Distribution by Type of Biomarker Detected
Table 19.23 Companion Diagnostics: Distribution by Biochemical Nature of Biomarker Detected
Table 19.24 Companion Diagnostics: Distribution by Type of Sample Used
Table 19.25 Companion Diagnostics: Distribution by Commercial Availability and Therapeutic Area
Table 19.26 Companion Diagnostics: Distribution by Year of Initiation of Development of Investigational Programs
Table 19.27 Companion Diagnostics: Distribution by Year of Approval of Marketed Products
Table 19.28 Companion Diagnostics: Distribution by Regulatory Authority Involved in the Approval of Marketed Programs
Table 19.29 Companion Diagnostics: Distribution by Expediated Review Designation and Type of Biomarker Detected
Table 19.30 Companion Diagnostic Developers: Distribution by Year of Establishment
Table 19.31 Companion Diagnostic Developers: Distribution by Company Size
Table 19.32 Companion Diagnostic Developers: Distribution by Company Ownership
Table 19.33 Companion Diagnostic Developers: Distribution by Location of Headquarters
Table 19.34 World Map Representation: Distribution by Geography
Table 19.35 Most Active Players: Distribution by Number of Marketed Products and Investigational Programs
Table 19.36 Most Active Players: Distribution by Number of Marketed Products
Table 19.37 Most Active Players: Distribution by Number of Target Disease Indications
Table 19.38 Partnerships and Collaborations: Distribution by Year of Partnership
Table 19.39 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.40 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.41 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 19.42 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 19.43 Partnerships and Collaborations: Distribution by Type of Therapeutic Area
Table 19.44 Partnerships and Collaborations: Distribution by Year and Type of Partners
Table 19.45 Most Active Players: Distribution by Number of Partnerships
Table 19.46 Partnerships and Collaborations: Regional Distribution
Table 19.47 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 19.48 World Map Representation: Regional Distribution of Amyloid Beta Biomarker Focused Clinical Trials
Table 19.49 World Map Representation: Regional Distribution of Tau Biomarker Focused Clinical Trials
Table 19.50 World Map Representation: Regional Distribution of BRCA Biomarker Focused Clinical Trials
Table 19.51 World Map Representation: Regional Distribution of HER Biomarker Focused Clinical Trials
Table 19.52 World Map Representation: Regional Distribution of HR Biomarker Focused Clinical Trials
Table 19.53 World Map Representation: Regional Distribution of PD-L1 Biomarker Focused Clinical Trials
Table 19.54 World Map Representation: Regional Distribution of BRAF Biomarker Focused Clinical Trials
Table 19.55 World Map Representation: Regional Distribution of EGFR Biomarker Focused Clinical Trials
Table 19.56 World Map Representation: Regional Distribution of KRAS Biomarker Focused Clinical Trials
Table 19.57 World Map Representation: Regional Distribution of MSI Biomarker Focused Clinical Trials
Table 19.58 World Map Representation: Regional Distribution of NRAS Biomarker Focused Clinical Trials
Table 19.59 World Map Representation: Regional Distribution of CCR5 Biomarker Focused Clinical Trials
Table 19.60 World Map Representation: Regional Distribution of ALK Biomarker Focused Clinical Trials
Table 19.61 World Map Representation: Regional Distribution of EGFR Biomarker Focused Clinical Trials
Table 19.62 World Map Representation: Regional Distribution of PD-L1 Biomarker Focused Clinical Trials
Table 19.63 World Map Representation: Regional Distribution of RET Biomarker Focused Clinical Trials
Table 19.64 World Map Representation: Regional Distribution of ROS Biomarker Focused Clinical Trials
Table 19.65 World Map Representation: Regional Distribution of AST Biomarker Focused Clinical Trials
Table 19.66 World Map Representation: Regional Distribution of BRCA Biomarker Focused Clinical Trials
Table 19.67 World Map Representation: Regional Distribution of CA-125 Biomarker Focused Clinical Trials
Table 19.68 World Map Representation: Regional Distribution of AR-V7 Biomarker Focused Clinical Trials
Table 19.69 Mergers and Acquisitions: Distribution by Type of Deal
Table 19.70 Mergers and Acquisitions: Distribution by Year of Deal
Table 19.71 Mergers and Acquisitions: Regional Distribution
Table 19.72 Mergers and Acquisitions: Continent-wise Distribution
Table 19.73 Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Table 19.74 Mergers and Acquisitions: Country-wise Distribution
Table 19.75 Mergers and Acquisitions: Distribution by Company Size
Table 19.76 Mergers and Acquisitions: Ownership Change Matrix
Table 19.77 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 19.78 Mergers and Acquisitions: Valuation by Acquisition Deal Multiples
Table 19.79 Key Players: Distribution by Number of Deals
Table 19.80 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 19.81 Clinical Trial Analysis: Distribution by Phase of Development
Table 19.82 Clinical Trial Analysis: Distribution by Sponsor
Table 19.83 Clinical Trial Analysis: Distribution by Recruitment Status
Table 19.84 Clinical Trial Analysis: Distribution by Therapy Design
Table 19.85 Clinical Trial Analysis: Distribution by Geography
Table 19.86 Clinical Trial Analysis: Distribution by Enrolled Patient Population
Table 19.87 Clinical Trial Analysis: Distribution by Most Popular Biomarkers
Table 19.88 Clinical Trial Analysis: Distribution by Moderately Popular Biomarkers
Table 19.89 Clinical Trial Analysis: Distribution by Less Popular / Preliminary Stage Biomarkers
Table 19.90 Other Emerging Biomarkers: Word Cloud
Table 19.91 Clinical Trial Analysis: Distribution of Trials of Most Popular Biomarkers by Trial Registration Year
Table 19.92 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Biomarkers by Trial Registration Year
Table 19.93 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Biomarkers by Trial Registration Year
Table 19.94 Clinical Trial Analysis: Distribution of Trials of Most Popular Biomarkers by Phase of Development
Table 19.95 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Biomarkers by Phase of Development
Table 19.96 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Biomarkers by Phase of Development
Table 19.97 Clinical Trial Analysis: Distribution of Trials of Most Popular Biomarkers by Sponsors
Table 19.98 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Biomarkers by Sponsors
Table 19.99 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Biomarkers by Sponsors
Table 19.100 Clinical Trial Analysis: Distribution of Trials for Most Popular Indications
Table 19.101 Clinical Trial Analysis: Distribution of Trials for Moderately Popular Indications
Table 19.102 Clinical Trial Analysis: Distribution of Trials for Less Popular and Other Indications
Table 19.103 Other Emerging Indications: Word Cloud
Table 19.104 Clinical Trial Analysis: Distribution of Trials of Most Popular Indications by Trial Registration Year
Table 19.105 Clinical Trial Analysis: Distribution of Trial of Moderately Popular Indications by Trial Registration Year
Table 19.106 Clinical Trial Analysis: Distribution of Trials of Less Popular and Other Indications by Trial Registration Year
Table 19.107 Clinical Trial Analysis: Distribution of Trials of Most Popular Indications by Phase of Development
Table 19.108 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Indications by Phase of Development
Table 19.109 Clinical Trial Analysis: Distribution of Trials of Less Popular and Emerging Indications by Phase of Development
Table 19.110 Clinical Trial Analysis: Distribution of Trials of Most Popular Indications by Sponsor
Table 19.111 Clinical Trial Analysis: Distribution of Trials of Moderately Popular Indications by Sponsor
Table 19.112 Clinical Trial Analysis: Distribution of Trials of Less Popular and Emerging Indications by Sponsor
Table 19.113 Clinical Trial Analysis: Distribution of Trials of Lung Cancer by Affiliated Biomarkers
Table 19.114 Clinical Trials Summary: Distribution of Trials of Breast Cancer by Affiliated Biomarkers
Table 19.115 Clinical Trials Summary: Distribution of Trials of Lymphoma by Affiliated Biomarkers
Table 19.116 Clinical Trials Summary: Distribution of Trials of Ovarian Cancer by Affiliated Biomarkers
Table 19.117 Clinical Trials Summary: Distribution of Trials of Prostate Cancer by Affiliated Biomarkers
Table 19.118 Clinical Trials Summary: Distribution of Trials of Melanoma by Affiliated Biomarkers
Table 19.119 Clinical Trials Summary: Distribution of Trials of Colon / Colorectal Cancer by Affiliated Biomarkers
Table 19.120 Clinical Trials Summary: Distribution of Trials of Head and Neck Cancer by Affiliated Biomarkers
Table 19.121 Biomarker-Driven Targeted Therapies: Distribution by Commercial Availability
Table 19.122 Biomarker-Driven Targeted Therapies: Distribution by Type of Molecule
Table 19.123 Biomarker-Driven Targeted Therapies: Distribution by Commercial Availability and Type of Molecule
Table 19.124 Biomarker-Driven Targeted Therapies: Distribution by Route of Administration
Table 19.125 Leading Biomarker-Driven Targeted Therapies: Distribution by Number of Companion Diagnostic Products / Programs
Table 19.126 Biomarker-Driven Targeted Therapy Developers: Distribution by Year of Establishment
Table 19.127 Biomarker-Driven Targeted Therapy Developers: Distribution by Company Size
Table 19.128 Biomarker-Driven Targeted Therapy Developers: Distribution by Company Ownership
Table 19.129 Biomarker-Driven Targeted Therapy Developers: Distribution by Location of Headquarters
Table 19.130 Leading Players: Distribution by Number of Biomarker-Driven Targeted Therapies
Table 19.131 Precision Medicine Software Solutions: Distribution by Type of Platform
Table 19.132 Precision Medicine Software Solutions: Distribution by Purpose of Software Applications
Table 19.133 Precision Medicine Software Solutions: Distribution by Type of Data Handled
Table 19.134 Precision Medicine Software Solutions: Distribution by Therapeutic Area
Table 19.135 Precision Medicine Software Solutions: Distribution by Type of End User
Table 19.136 Precision Medicine Software Solution Developers: Distribution by Year of Establishment
Table 19.137 Precision Medicine Software Solution Developers: Distribution by Company Size
Table 19.138 Precision Medicine Software Solution Developers: Distribution by Location of Headquarters
Table 19.139 World Map Representation: Distribution by Geography
Table 19.140 Global Companion Diagnostics Development Services Market, 2022-2035 (USD Million)
Table 19.141 Global Companion Diagnostics Development Services Market: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Table 19.142 Global Companion Diagnostics Development Services Market: Distribution by Type of Analytical Technique, 2022-2035 (USD Million)
Table 19.143 Global Companion Diagnostics Development Services Market: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 19.144 Global Companion Diagnostics Development Services Market: Distribution by Region, 2022-2035 (USD Million)
Table 19.145 Companion Diagnostics Development Services Market in North America, 2022-2035 (USD Million)
Table 19.146 Companion Diagnostics Development Services Market in North America: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Table 19.147 Companion Diagnostics Development Services Market in North America: Distribution by Type of Analytical Technique, 2022-2035 (USD Million)
Table 19.148 Companion Diagnostics Development Services Market in North America: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 19.149 Companion Diagnostics Development Services Market in Europe, 2022-2035 (USD Million)
Table 19.150 Companion Diagnostics Development Services Market in Europe: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Table 19.151 Companion Diagnostics Development Services Market in Europe: Distribution by Type of Analytical Technique, 2022-2035 (USD Million)
Table 19.152 Companion Diagnostics Development Services Market in Europe: Distribution by Therapeutic Area, 2022-2035 (USD Million)
Table 19.153 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of the World, 2022-2035 (USD Million)
Table 19.154 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of the World: Distribution by Type of Service Offered, 2022-2035 (USD Million)
Table 19.155 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of The World: Distribution by Type of Analytical Technique Offered, 2022-2035 (USD Million)
Table 19.156 Companion Diagnostics Development Services Market in Asia-Pacific and Rest of the World: Distribution by Therapeutic Area, 2022-2035 (USD Million)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

20/20 GeneSystems
2bPrecise (acquired by AccessDX)
3D Medicines
4D Path
A&G Pharmaceutical
A2 Biotherapeutics
AB-BIOTICS
Abbott
AbbVie
Abcam
Abnova
AccuGenomics
ACOBIOM (formerly known as Skuldtech)
MD Diagnostics (acquired by ACT Genomics)
actMED
Adial Pharmaceuticals
Admera Health
Advanced Cell Diagnostics
Agena Bioscience (acquired by Mesa Laboratories)
Agendia
Agilent Technologies
Agios Pharmaceuticals (acquired by Servier)
Ainnova Tech
AIQ Solutions
AKESOgen (acquired by Tempus)
Akoya Biosciences
Allergan (acquired by AbbVie)
Almac Diagnostic Services
AltheaDx
Altis Labs
Alva10
Amarantus BioScience
AMedSU
Amgen
Amoy Diagnostics (AmoyDx)
Anagenics
Anavex Life Sciences
ANGLE
ApoCell (acquired by Precision for Medicine)
Apogenix
Applied BioCode
ARIAD Pharmaceuticals (acquired by Takeda)
Ariel Precision Medicine
Array BioPharma (acquired by Pfizer)
ARUP Laboratories
Ascenda Biosciences
ASPIRA Women's Health (formerly known as Vermillion)
Astarte Medical
Astellas Pharma
Asterand Bioscience (acquired by BioIVT)
AstraZeneca
Asuragen (acquired by Bio-Techne)
Atlas Link Biotech
AVA LifeScience
AVEO Oncology
Azenta Life Sciences (formerly known as Brooks Automation)
Bayer
Baylor Genetics
Beaufort
BeiGene
BerGenBio
BGI Genomics
Biocartis
Biocept
BioClavis
biocrates life sciences
Biodesix
Biofidelity
Biogazelle (acquired by CellCarta)
BioIVT (formerly known as BioreclamationIVT)
Biolidics (formerly known as Clearbridge BioMedics)
BioMarin Pharmaceutical
BioMarker Strategies
BiomarkerBay
Biomedical Advanced Research and Development Authority (BARDA)
bioMérieux
BioNTech
Bio-Techne
BioVariance
Bliss Biopharmaceutical
Blueprint Medicines
Boehringer Ingelheim
Bosch Healthcare Solutions
Brainomix
Breakthrough Genomics
Bristol Myers Squibb
Burning Rock Biotech
C2i Genomics
Canadian Pathology Quality Assurance
CANbridge Pharmaceuticals
Cancer Treatment Centers of America (CTCA)
CancerIQ
Canon Medical Systems
Canopy Biosciences (acquired by Bruker)
Caris Life Sciences
CD Genomics
Celgene (acquired by Bristol Myers Squibb)
CellCarta (formerly known as Caprion - HistoGeneX)
Anagenics (formerly known as Cellmid)
Cenetron Diagnostics (acquired by Versiti)
CENTOGENE
Cerba Research
Charles River Laboratories
CHEPLAPHARM
Chipscreen Biosciences
Chugai Pharmaceutical (acquired by Roche)
CIRCULOGENE
CirQuest Labs (acquired by MLM Medical Labs)
Cizzle Biotechnology
ClearPoint Diagnostic Laboratories (acquired by Quest Diagnostics)
Cleveland HeartLab (acquired by Quest Diagnostics)
Clinical Reference Laboratory
Clovis Oncology
Cofactor Genomics
Cohesic
Community Clinical Oncology Research Network
CompanDx (formerly known as Compandia)
Compass Laboratory Services
ConcertAI
Concr
Context Therapeutics
CORE Diagnostics (acquired by Canopy Biosciences)
Core Precision
Corgenix Medical (subsidiary of ORGENTEC Diagnostik)
Creative Biolabs
Creatv MicroTech
Cureline
CureMatch
Curii
CytoTest
Daiichi Sankyo
Data4Cure
Debiopharm
deCODE genetics
Deep Lens
Definiens (acquired by MedImmune)
Denovo Biopharma
DiaCarta
Diaceutics
DiaDx
DiagnosTear
DiaSorin
Discovery Life Sciences
DNAnexus
Dr. Falk Pharma
Eisai
Eledon Pharmaceuticals (formerly known as Novus Therapeutics)
Eli Lilly
Elthera
Elucigene Diagnostics (acquired by Yourgene Health)
Elypta
Empire Genomics
Endpoint Health
Enzo Biochem
EONE-Diagnomics Genome Center (EDGC)
Epic Sciences
Epizyme
ESN Cleer
Eurobio Scientific (formerly known as Diaxonhit)
European Organisation for the Research and Treatment of Cancer
Eutropics Pharmaceuticals
Ex5 Genomics (acquired by Yourgene Health)
Exagen
Exosome Diagnostics (acquired by Bio-Techne)
Fabric Genomics (formerly known as Omicia)
FALCO biosystems
Farsight Genome Systems
Fast Track Diagnostics (acquired by Siemens Healthineers)
Ferring Pharmaceuticals
Five Prime Therapeutics (acquired by Amgen)
Flagship Biosciences
Flatiron Health
Foundation Medicine
Freenome
Frontage Laboratories
Gencurix
GeneCast Biotechnology
GeneCentric Therapeutics
Genedata
Genelex (acquired by Invitae)
Genentech (acquired by Roche)
Geneseeq Technology
Geneseq Biosciences
Genetron Health
Geneuity Clinical Research Services
GENEWIZ (acquired by Azenta Life Sciences)
geneXplain
Genomas (acquired by Rennova Health)
Genomenon
Genomictree
Genomind
GenomOncology
GenomSys
Genoptix (acquired by Novartis)
Genosity (acquired by Invitae)
Genospace
GenXys
Gilead Sciences
GlaxoSmithKline
GNS Healthcare
Golden Helix
GRAIL (acquired by Illumina)
GreenM
Guangzhou Wondfo Biotech
Guardant Health
Guardian Research Network
Haihe Biopharma
Halozyme
HalioDx (acquired by Veracyte)
Hangzhou Normal University
HangZhou Watson Biotech
Healthgen
Helomics (formerly known as Precision Therapeutics)
Hematogenix Pharma Services
HengRui
HiberCell
HistoCyte Laboratories
HistoGeneX
HistologiX
Horizon Discovery
HTG Molecular Diagnostics
Human Longevity
Hummingbird Diagnostics
Hygea Precision Medicine
Hyperfine
Ibex Medical Analytics
IBM
iCellate Medical
ICON Specialty Laboratories (formerly known as MolecularMD)
IDbyDNA
Idera Pharmaceuticals
Ignyta (acquired by Roche)
Ikonisys
Illumina
Imaginostics
Immunex (acquired by Amgen)
ImmunoGen
IMPACT Therapeutics
In Vitro ADMET Laboratories (acquired by Discovery Life Sciences)
IncellDx
Incyte (acquired by Novartis)
InDex Pharmaceuticals
Indivior
iNDX.Ai
InformedDNA
Inivata
InnaVirVax
Inotrem
INOVIO Pharmaceuticals
Insight Genetics (acquired by Oncocyte)
InsightRX
Inspirata
IntegraGen (acquired by OncoDNA)
IntelliHealth Solutions
International Development Association (IDA)
Intero Life Sciences
Interpace Biosciences (formerly known as Interpace Diagnostics)
Intertrust Technologies
Intezyne Technologies
IntrinsiQ Specialty Solutions
Invitae (formerly known as ArcherDx)
Invivoscribe
IQVIA
Janssen Pharmaceutical (acquired by Johnson & Johnson)
JSR Life Sciences
Kaneka
Kartos Therapeutics
Keen Eye Technologies
KingMed Diagnostics
Kronos Bio
Kura Oncology
Kyowa Kirin
Lab21 Healthcare (part of Novacyt)
Labcorp (formerly known as Covance)
LaserGen (acquired by Agilent Technologies)
Leica Biosystems (acquired by Danaher)
LEO Pharma
Lexent Bio (acquired by Foundation Medicine)
Lifebit
LifeOmic Health
Linkage Biosciences
Locus Biosciences
Loxo Oncology (acquired by Eli Lilly)
Lucence
Luminex (acquired by DiaSorin)
LunaPBC
M2GEN
MacroGenics
MapKure (owned by BeiGene and SpringWorks Therapeutics)
Massachusetts General Hospital
MC Diagnostics
MD Biosciences (acquired by MLM Medical Labs)
MDNA Life Sciences
MDxHealth (formerly known as OncoMethylome Sciences)
Med Fusion (acquired by Quest Diagnostics)
MEDx (Suzhou) Translational Medicine (formerly known as QIAGEN (Suzhou) Translational Medicine)
MedGenome
MEDICAL & BIOLOGICAL LABORATORIES (acquired by JSR Life Sciences)
Medipredict
Medneon (acquired by Invitae)
MEDx Translational Medicine (formerly known as QIAGEN (Suzhou) Translational Medicine)
Memorial Sloan Kettering Cancer Center
Menarini Silicon Biosystems
Merck
Mesa Laboratories
Metabolon
Metanomics Health (acquired by BIOCRATES Life Sciences)
Mirati Therapeutics (formerly known as MethylGene)
Mission Bio
MLM Medical Labs
Molecular Health
MolecularMatch
Monogram Biosciences (acquired by Laboratory Corporation of America)
Montpellier University Hospital
Mosaic Laboratories (acquired by Caprion-HistoGeneX)
Mount Sinai Health System Clinical Outreach Laboratories (acquired by Labcorp)
mymo.AI
Myriad Genetics
NanoString Technologies
NantHealth
Nashville Biosciences
Natera
National Cancer Center Hospital
Navigate BioPharma Services
NeoGenomics Laboratories
NG Biotech
NGeneBio
NGX Bio
Nichirei Biosciences
Nodality
N-of-One (acquired by QIAGEN)
North American Science Associates (NAMSA)
Novartis
Novodiax
Novogene
NuSirt Biopharma
Ocean Ridge Biosciences (acquired by Frontage Laboratories)
OcnoDNA
Olink Proteomics
OmniSeq
Oncimmune USA (subsidiary of Oncimmune)
Oncocyte
OncoMed Pharmaceuticals
Oncoquest Laboratories
Oncora Medical
OncXerna Therapeutics
OneOncology
Oracle
Orion Health
Outcomes4Me
OWL Metabolomics (formerly known as OWL GENOMICS)
Oxford BioDynamics (OBD)
Oxford Cancer Biomarkers
Pangea Oncology
Paragon Genomics
Parexel
Parkway Laboratories
Partner Therapeutics
PathAI
Perceiv AI
Personal Genome Diagnostics (acquired by Labcorp)
Personalis
Pfizer
Pharmaceutical Product Development (acquired by Thermo Fisher Scientific)
PharmaLex
Pharmatech (acquired by Caris Life Sciences)
Pharmatics
PhenoTips
Philips
Phoenix Molecular Designs
Phosphorus
PierianDx
Pierre Fabre
Pillar Biosciences
Pinnacle Healthcare (acquired by University of Pittsburgh Medical Center)
PipelineRx (acquired by CarePathRx)
Precision Digital Health
Precision for Medicine
Precision Health Informatics (subsidiary of Texas Oncology)
Precision Health Software
Progenika Biopharma
ProMedDx (acquired by Precision for Medicine)
Promega
Prometheus (formerly known as Precision IBD)
ProMIS Neurosciences (formerly known as Amorfix Life Sciences)
Protagen Diagnostics
Protavio (formerly known as ProtATonce)
Provista Diagnostics (acquired by Todos Medical)
Psomagen (formerly known as Macrogen)
Psyche Systems
Puma Biotechnology
Q² Solutions (acquired by IQVIA)
QED Therapeutics (subsidiary of BridgeBio Pharma)
QIAGEN
Qlucore
QualTek Molecular Laboratories (acquired by Discovery Life Sciences)
Quanterix
Queen’s University Belfast
Quest Diagnostics
Qynapse
Race Oncology
Radius Health
Randox Biosciences (part of Randox Laboratories)
RareCyte
Razor Genomics (acquired by Oncocyte)
R-Biopharm
Regeneron Pharmaceuticals
regenold
Regulus Therapeutics
Renalytix
Repertoire Genesis
ResearchDx
Resolomics
Resolution Bioscience (acquired by Agilent Technologies)
Resonance Health
ResourcePath
Reveal Biosciences (acquired by CellCarta)
Riken Genesis
Roche
Roche Tissue Diagnostics (formerly known as Ventana Medical Systems)
RxMx
SAGA Diagnostics
Saladax Biomedical
Sanofi
Sanomics
SAP
Saphetor
SCA Robotics
Science 37
Sebia
Sengenics
Sentieon
SeraCare Life Sciences (acquired by LCG)
Seven Bridges
Shanghai Biotechnology (formerly known as ShanghaiBio)
Shanghai Henlius Biotech
Shanghai Promega Biological Products
Sheba Medical Center
Shuwen Biotech
Siemens Healthineers (formerly known as Siemens Healthcare)
Simcere Pharmaceutical
Sirius Genomics
SkylineDx
SocialGenomics MOONSHOT
SomaLogic
Sonrai Analytics
SOPHiA GENETICS
Source BioScience
Spectrum Pharmaceuticals
Spesana
SRL Diagnostics
Stone Checker Software
Strand Life Sciences
Sundance Diagnostics
Sunquest Information Systems (acquired by Roper Industries)
Svar Life Science (formerly known as Euro Diagnostica)
Syapse
Sysmex Inostics
Tabula Rasa HealthCare (formerly known as CareKinesis)
TaiRx
Takeda Pharmaceutical
Taliaz
Targos Molecular Pathology (acquired by Discovery Life Sciences)
Teladoc Health
TellBio
Tempus
Tepnel Pharma Services
Terumo Medical
TESARO (acquired by GlaxoSmithKline)
The Intelligent Tissue Group
The Max Planck Society
The University of Cambridge
Thermo Fisher Scientific
TIGAR Health Technologies
Tissue Diagnostics
Tissue Solutions (acquired by BioIVT)
Todos Medical
Tokyo Medical and Dental University (TMDU)
Tolero Pharmaceuticals
Translational Software
Trialbee
Turning Point Therapeutics
Twist Bioscience
Tymora Analytical Operations
uBiome
UgenTec
UmanDiagnostics (acquired by Quanterix)
uMETHOD
Unilabs
University of Bonn
University of Missouri
Valley Biomedical Products & Services (acquired by BioIVT)
Variantyx
Verastem Oncology
Veridex (subsidiary of Johnson & Johnson)
Verily Life Sciences (formerly known as Google Life Sciences)
Versiti
Viatris
Visiopharm
Vivia Biotech
Vyant Bio (formerly known as Cancer Genetics)
Wave Life Sciences
Xeptagen
Xiamen Spacegen
XIFIN
Yemaachi Biotech
Yourgene Health
YouScript (acquired by Invitae)

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4731EUR$4,799USD£3,912GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6899EUR$6,999USD£5,705GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€17743EUR$17,999USD£14,671GBP

Scope of the Report

Amongst other elements, the report includes:

The report features detailed transcripts of interviews held with the following industry stakeholders:

Key Questions Answered

Table of Contents

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

Companion Diagnostics Market Report and Forecast 2024-2032

Companion Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

Global Oncology Companion Diagnostics Market Report 2024

Companion Diagnostics Market Report by Product & Service, Indication, End User, and Region 2024-2032

Companion Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030